Yang et al., 2015 - Google Patents
Nuclear localization signal-enhanced polyurethane-short branch polyethylenimine-mediated delivery of Let-7a inhibited cancer stem-like properties by targeting the 3 …Yang et al., 2015
View HTML- Document ID
- 9366576594004946990
- Author
- Yang M
- Chen M
- Huang P
- Wang C
- Chang Y
- Yang Y
- Lo W
- Sung W
- Liao Y
- Lee Y
- Chang Y
- Tseng L
- Chen Y
- Ma H
- Publication year
- Publication venue
- Cell transplantation
External Links
Snippet
Anaplastic astrocytoma (AA) is a grade III glioma that often occurs in middle-aged patients and presents a uniformly poor prognosis. A small subpopulation of cancer stem cells (CSCs) possessing a self-renewing capacity is reported to be responsible for tumor recurrence and …
- 230000001404 mediated 0 title abstract description 39
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of oncogenic miR-21 | |
| Yu et al. | Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression | |
| Yang et al. | Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI | |
| Costa et al. | MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression | |
| Dang et al. | The role of hypoxia-induced miR-210 in cancer progression | |
| Chen et al. | Role of microRNAs in glioblastoma | |
| Kouri et al. | miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma | |
| Ghosh et al. | A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells | |
| Karsy et al. | Current progress on understanding microRNAs in glioblastoma multiforme | |
| Wu et al. | Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer | |
| Gilles et al. | Personalized RNA medicine for pancreatic cancer | |
| Jee et al. | Silencing of miR20a is crucial for Ngn1-mediated neuroprotection in injured spinal cord | |
| Tang et al. | Disturbing miR-182 and-381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4 | |
| Silber et al. | microRNAs in gliomas: small regulators of a big problem | |
| Garg | Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer | |
| Krichevsky et al. | Oligonucleotide therapeutics as a new class of drugs for malignant brain tumors: targeting mRNAs, regulatory RNAs, mutations, combinations, and beyond | |
| Yang et al. | Nuclear localization signal-enhanced polyurethane-short branch polyethylenimine-mediated delivery of Let-7a inhibited cancer stem-like properties by targeting the 3′-UTR of HMGA2 in anaplastic Astrocytoma | |
| Lee et al. | MicroRNA142-3p promotes tumor-initiating and radioresistant properties in malignant pediatric brain tumors | |
| He et al. | microRNA-221 enhances MYCN via targeting nemo-like kinase and functions as an oncogene related to poor prognosis in neuroblastoma | |
| Dhuri et al. | Therapeutic potential of chemically modified, synthetic, triplex peptide nucleic acid–based oncomir inhibitors for cancer therapy | |
| Toraih et al. | Deregulated microRNA signature following glioblastoma irradiation | |
| Deforzh et al. | Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma | |
| Kim et al. | Single-factor SOX2 mediates direct neural reprogramming of human mesenchymal stem cells via transfection of in vitro transcribed mRNA | |
| Sharma et al. | Targeting non-coding RNA for glioblastoma therapy: the challenge of overcomes the blood-brain barrier | |
| Song et al. | Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush |